The New Jersey Supreme Court on Wednesday said plaintiff expert testimony in a mass tort case alleging that the pharmaceutical giant Hoffmann-La Roche’s anti-acne drug Accutane led to development of Crohn’s disease was properly excluded.

The unanimous ruling, a reversal of the Appellate Division, is a major victory for Hoffmann-La Roche, which was defending more than 2,100 Accutane lawsuits in New Jersey, all of which were consolidated in Atlantic County. It reinstates the decision on admissibility originally issued by Superior Court Judge Nelson Johnson, who rejected the testimony of the plaintiffs’ experts.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]